Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a Trop-2-targeting antibody via a pH-sensitive linking moiety, achieving a good drug:antibody ratio. In a phase I-II study involving metastatic TNBC (mTNBC) individuals, SG achieved an overall response rate of 33.3% and a median response period of 7.7 months. The phase III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving median progression-free survival and median overall survival compared to chemotherapy. Common side effects include neutropenia, nausea, and fatigue. This article highlights the clinical potential, pharmacokinetics, safety profile, and resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy. The review also discusses current strategies for managing adverse reactions and sequencing ADC treatments in clinical practice, along with the predicted basis of resistance. The optimal sequencing of SG relative to other ADCs, such as trastuzumab deruxtecan or T-DXd, remains an evolving question, especially as newer agents with distinct mechanisms of action and safety profiles enter the field. Further research is essential to establish evidence-based strategies for sequencing SG and addressing disease progression post-ADC therapy.
23 January 2025 in Results in Surfaces and Interfaces
This proceeding volume has been retracted from the publication because we found some solid reasons to believe that it has infringed our integrity criteria and now presents a risk for our journal and scholarly science in general. Different types of malpractice are involved, in particular citation manipulation and inappropriate references. We are extremely concerned by such malpractice which considerably impacts the image of our title and our Publisher’s reputation. For further details, please refer to our publishing ethics policies. If you have any questions, please contact us at contact@webofconferences.org See the retraction notice E3S Web of Conferences 505, 00001 (2024), https://doi.org/10.1051/e3sconf/202450500001
2 July 2024 in International Journal on Interactive Design and Manufacturing (IJIDeM)
Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behaviour and limited treatment options. While therapies like checkpoint inhibitors and PARP inhibitors (PARPi) offer some benefit, chemotherapy remains ineffective beyond the first line of treatment. Antibody-drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a TROP-2-targeting antibody via a pH-sensitive linking moiety, achieving an good drug:antibody ratio. Infused on Days 1 and 8 over 21 days, SG utilizes a moderately stable linker to ensure effective tumor targeting while minimizing side effects like diarrhea. By delivering SN-38 into the tumor niche, it induces double-stranded DNA damage, promoting cancer apoptosis. In a phase I-II study involving 108 mTNBC patients, SG achieved an overall response rate (ORR) of 33.3% and a median response period of 7.7 months. Common side effects included neutropenia, nausea, and fatigue. This review highlights clinical potential, pharmacokinetics, safety profile, resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy.